Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Current Deferred Revenue (2016 - 2020)

Historic Current Deferred Revenue for Amicus Therapeutics (FOLD) over the last 9 years, with Q1 2020 value amounting to $1.2 million.

  • Amicus Therapeutics' Current Deferred Revenue fell 5454.55% to $1.2 million in Q1 2020 from the same period last year, while for Mar 2020 it was $1.2 million, marking a year-over-year decrease of 5454.55%. This contributed to the annual value of $1.2 million for FY2019, which is 7727.27% down from last year.
  • Latest data reveals that Amicus Therapeutics reported Current Deferred Revenue of $1.2 million as of Q1 2020, which was down 5454.55% from $1.2 million recorded in Q4 2019.
  • In the past 5 years, Amicus Therapeutics' Current Deferred Revenue ranged from a high of $18.8 million in Q2 2017 and a low of $1.2 million during Q4 2019
  • Over the past 5 years, Amicus Therapeutics' median Current Deferred Revenue value was $5.4 million (recorded in 2018), while the average stood at $6.6 million.
  • Per our database at Business Quant, Amicus Therapeutics' Current Deferred Revenue plummeted by 8541.11% in 2018 and then skyrocketed by 9090.91% in 2019.
  • Amicus Therapeutics' Current Deferred Revenue (Quarter) stood at $13.8 million in 2016, then tumbled by 44.04% to $7.8 million in 2017, then decreased by 29.03% to $5.5 million in 2018, then tumbled by 77.27% to $1.2 million in 2019, then changed by 0.0% to $1.2 million in 2020.
  • Its Current Deferred Revenue stands at $1.2 million for Q1 2020, versus $1.2 million for Q4 2019 and $5.2 million for Q3 2019.